AI partnership expansion with Google Cloud comes into focus
Waystar Holding (WAY) is back on investor radars after announcing an expanded collaboration with Google Cloud that centers on deeper use of Gemini AI models and data infrastructure in healthcare payments.
The move targets more automation across complex revenue cycle workflows, including new agentic AI use cases that combine financial and clinical data, and could influence how investors think about the company’s long term technology roadmap.
See our latest analysis for Waystar Holding.
Despite the AI partnership headlines, Waystar’s share price return shows a mixed picture, with a 9.82% 1-month gain from a last close of US$24.61, a 21.55% year-to-date decline, and a 32.67% 1-year total shareholder return loss. This suggests recent optimism is emerging after a weaker stretch.
If this kind of healthcare AI story interests you, it could be worth scanning the wider space using a screener focused on 33 healthcare AI stocks
With the stock still down 21.55% year to date despite a recent 9.82% 1 month rebound and trading at what some might view as a discount to analyst targets, investors may be asking whether this is a reset that offers upside or if the market is already incorporating expectations for future growth.
Most Popular Narrative: 33.5% Undervalued
Waystar Holding’s most followed narrative pegs fair value at $37.00, compared with the last close of $24.61, which frames the current AI partnership news in a very different light.
The analysts have a consensus price target of $50.385 for Waystar Holding based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $54.0, and the most bearish reporting a price target of just $45.0.
Want to see what kind of revenue path and margin profile sit behind that fair value and those earnings expectations? The narrative leans heavily on rising profitability, compounding earnings and a future profit multiple that assumes the market keeps rewarding growth. If you want to understand which specific financial levers carry the most weight in that view, the full breakdown lays it out clearly.
Result: Fair Value of $37.00 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, higher leverage from the US$1.25b Iodine deal and the risk of pricing pressure from larger provider groups could quickly challenge that earnings power story.
Find out about the key risks to this Waystar Holding narrative.
Another Way To Look At Value
The fair value narrative leans on future earnings, but the current P/E of 42.1x tells a sharper story. It sits well above the fair ratio of 27.3x, the peer average of 27.8x, and the global Healthcare Services average of 29.1x, which points to clear multiple risk if sentiment cools.
For a closer look at how these valuation gaps stack up against similar names, it can help to break down the numbers side by side. From there, you can consider whether earnings delivery can keep justifying this premium or whether you would prefer to wait for the ratio to move closer to the fair ratio. See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Given the mixed tone of the recent returns and valuation signals, it can help to move quickly, review the underlying metrics yourself, and then weigh up the 4 key rewards.
Looking for more investment ideas?
If you stop with just one stock, you miss the chance to spot other opportunities that fit your style and risk comfort, so keep widening your field of vision.
- Zero in on potential value candidates by scanning 47 high quality undervalued stocks that pair solid fundamentals with prices some investors may view as appealing.
- Strengthen your defense by checking 74 resilient stocks with low risk scores that score well on resilience so your portfolio is not leaning on just a few higher risk names.
- Spot future standouts early by reviewing the screener containing 26 high quality undiscovered gems before they attract broader attention and pricing adjusts.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com